MoonLake Immunotherapeutics (MLTX)

Precedente Chiudi:

$43.66

Aprire:

$43.95

Volume 24 ore:

37,107

Capitalizzazione di mercato:

$2.75B

Reddito:

-

Utile/perdita netta:

$-36.01M

Rapporto P/E:

-35.84

EPS:

-1.1692

Flusso di cassa netto:

$-42.78M

1 W Prestazione:

-2.19%

1M Prestazione:

-9.39%

6M Prestazione:

+4.28%

1 anno Prestazione:

+54.84%

Intervallo 1D:

$41.92

$44.00

Portata 52W:

$24.31

$64.98

MoonLake Immunotherapeutics Stock (MLTX) Company Profile

Nome

MoonLake Immunotherapeutics

Settore

Healthcare (1223)

Industria

Biotechnology (698)

Telefono

-

Indirizzo

Dorfstrasse 29, Zug

Dipendente

0

Cinguettio

Prossima data di guadagno

2024-06-05

Ultimi documenti SEC

MLTX's Discussions on Twitter

MoonLake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-08	Iniziato	Citigroup	Buy
2023-11-02	Iniziato	Stifel	Buy
2023-09-14	Downgrade	Bryan Garnier	Buy → Neutral
2023-08-31	Iniziato	Needham	Buy
2023-06-15	Iniziato	Barclays	Equal Weight
2023-05-01	Iniziato	Guggenheim	Buy
2023-03-22	Iniziato	Wedbush	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2023-02-14	Iniziato	Cantor Fitzgerald	Overweight
2023-02-02	Iniziato	Bryan Garnier	Buy
2022-11-11	Iniziato	Jefferies	Buy
2022-08-25	Iniziato	SVB Leerink	Outperform
2022-07-21	Iniziato	H.C. Wainwright	Buy
2022-07-07	Iniziato	Cowen	Outperform

Mostra tutto

MoonLake Immunotherapeutics Borsa (MLTX) Ultime notizie

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire Inc.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

GlobeNewswire Inc.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

GlobeNewswire Inc.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Benzinga

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

GlobeNewswire Inc.

Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?

Zacks Investment Research

MoonLake Immunotherapeutics Azioni (MLTX) Dati Finanziari

MoonLake Immunotherapeutics (MLTX) Reddito netto 2024

MoonLake Immunotherapeutics (MLTX) Flusso di cassa 2024

MoonLake Immunotherapeutics (MLTX) Utile per azione 2024

MoonLake Immunotherapeutics Azioni (MLTX) insider trading